200 related articles for article (PubMed ID: 29669753)
1. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
Kumar A; Vardhana S; Moskowitz AJ; Porcu P; Dogan A; Dubovsky JA; Matasar MJ; Zhang Z; Younes A; Horwitz SM
Blood Adv; 2018 Apr; 2(8):871-876. PubMed ID: 29669753
[TBL] [Abstract][Full Text] [Related]
2. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
4. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
5. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
Gopal AK; Schuster SJ; Fowler NH; Trotman J; Hess G; Hou JZ; Yacoub A; Lill M; Martin P; Vitolo U; Spencer A; Radford J; Jurczak W; Morton J; Caballero D; Deshpande S; Gartenberg GJ; Wang SS; Damle RN; Schaffer M; Balasubramanian S; Vermeulen J; Cheson BD; Salles G
J Clin Oncol; 2018 Aug; 36(23):2405-2412. PubMed ID: 29851546
[TBL] [Abstract][Full Text] [Related]
7. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Dubovsky JA; Beckwith KA; Natarajan G; Woyach JA; Jaglowski S; Zhong Y; Hessler JD; Liu TM; Chang BY; Larkin KM; Stefanovski MR; Chappell DL; Frissora FW; Smith LL; Smucker KA; Flynn JM; Jones JA; Andritsos LA; Maddocks K; Lehman AM; Furman R; Sharman J; Mishra A; Caligiuri MA; Satoskar AR; Buggy JJ; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2013 Oct; 122(15):2539-49. PubMed ID: 23886836
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
12. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Bhatt V; Alejandro L; Michael A; Ganetsky A
Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
14. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Forero-Torres A; Ramchandren R; Yacoub A; Wertheim MS; Edenfield WJ; Caimi P; Gutierrez M; Akard L; Escobar C; Call J; Persky D; Iyer S; DeMarini DJ; Zhou L; Chen X; Dawkins F; Phillips TJ
Blood; 2019 Apr; 133(16):1742-1752. PubMed ID: 30803990
[TBL] [Abstract][Full Text] [Related]
15. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
16. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
Fox LC; Yannakou CK; Ryland G; Lade S; Dickinson M; Campbell BA; Prince HM
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]